Vaxart to Showcase its COVID-19 and Norovirus Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2024
Vaxart, Inc. (VXRT)
Last vaxart, inc. earnings: 3/19 04:01 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
SOUTH SAN FRANCISCO, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it will present research featuring its COVID-19 and norovirus oral pill vaccine candidates at the World Vaccine Congress Europe 2024 taking place in Barcelona, Spain on October 28-31, 2024. Vaxart’s mission is to improve global public health by developing a transformative oral tablet vaccine platform. With multiple promising clinical-stage programs, including those targeting COVID-19 and norovirus, the Company is committed in solving serious health challenges facing society. Vaxart’s differentiated platform has generated both systemic and mucosal immune responses and demonstrated a favorable safety and tolerability profile in clinical trials, reinforcing its potential of bringing worldwide game changing solutions. Presentation Information: Title: Oral Covid Vaccine - Clinical Update from Phase 1 to Phase 2BSpeaker: Dr. James F. Cummings, Chief Medical OfficerDate:
Show less
Read more
Impact Snapshot
Event Time:
VXRT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VXRT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VXRT alerts
High impacting Vaxart, Inc. news events
Weekly update
A roundup of the hottest topics
VXRT
News
- Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Vaxart Provides Business Update and Reports Third Quarter 2024 Financial ResultsGlobeNewswire
- Vaxart to Host Third Quarter 2024 Business Update and Financial Results Conference Call on November 13GlobeNewswire
- Vaxart to Present Norovirus Data at IDWeek 2024 Underscoring Commitment to Address Significant Unmet NeedGlobeNewswire
- Dr. Wouter Latour Joins PharmaJet as Chief Executive Officer [Yahoo! Finance]Yahoo! Finance
VXRT
Earnings
- 11/13/24 - Beat
VXRT
Sec Filings
- 11/13/24 - Form 10-Q
- 11/13/24 - Form 8-K
- 10/8/24 - Form 424B5
- VXRT's page on the SEC website